Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Int J Mol Sci. 2024 Jul 11;25(14):7592. doi: 10.3390/ijms25147592.
There is increasing evidence that vitamin D (VitD) supplementation may reduce inflammation in individuals with multiple sclerosis (MS). The aim of this study was to evaluate the effect of different doses of VitD on selected markers of inflammation in patients with relapsing-remitting MS (RRMS). Participants were divided depending on the supplemented dose of VitD into a high-dose (2000 IU/d; HD) group and a low-dose (15,960 IU/month; LD) group ( = 23 and = 29, respectively). The concentration of 25(OH)D and the levels of CXCL16, PTX3, ALCAM, IL-1RA, and OPG were measured initially and after six months of VitD supplementation in blood serum. A significant increase in the concentrations of CXCL16, PTX3, and OPG was observed during the study ( = 0.02, = 0.01, and < 0.01, respectively). Furthermore, a higher increase in PTX3 and OPG in the LD group was observed ( = 0.04 and = 0.03, respectively). A significant positive correlation was observed between the 25(OH)D serum concentration and PTX3 (R = 0.28, < 0.05) and OPG (R = 0.28, < 0.05) only at the beginning of the study. In patients with RRMS, such doses of VitD might be too low to induce obvious beneficial effects on the pro-inflammatory and inflammatory balance.
越来越多的证据表明，维生素 D（VitD）补充剂可能会减轻多发性硬化症（MS）患者的炎症。本研究旨在评估不同剂量的 VitD 对复发缓解型多发性硬化症（RRMS）患者的某些炎症标志物的影响。根据补充的 VitD 剂量，参与者被分为高剂量（2000IU/d；HD）组和低剂量（15960IU/月；LD）组（分别为 23 人和 29 人）。在血清中，最初和 VitD 补充六个月后测量了 25（OH）D 浓度和 CXCL16、PTX3、ALCAM、IL-1RA 和 OPG 水平。在研究过程中，观察到 CXCL16、PTX3 和 OPG 的浓度显著增加（分别为 0.02、0.01 和 ＜0.01）。此外，在 LD 组中观察到 PTX3 和 OPG 的增加更高（分别为 0.04 和 0.03）。在研究开始时，观察到血清 25（OH）D 浓度与 PTX3（R = 0.28，＜0.05）和 OPG（R = 0.28，＜0.05）之间存在显著正相关。在 RRMS 患者中，VitD 的这种剂量可能太低，无法对促炎和炎症平衡产生明显的有益影响。
